InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
64,092.88
(
1.91%
)
Post# of 251706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: frontiers post# 182980

Monday, 10/20/2014 1:47:28 PM

Monday, October 20, 2014 1:47:28 PM

Post# of 251706

ACHN—…your statement applies to every single HCV nuke in development now...not just to ACH-3422…

Of course; what’s unique about ACH-3422 is that some sell-side analysts have hyped the monotherapy data to be presented at AASLD as some kind of pivotal moment for the HCV arena.

Moreover, you've asserted on various occasions that ACH-3422's success is a fait accompli.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up